GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 29.40
Bid: 29.20
Ask: 29.90
Change: -0.35 (-1.18%)
Spread: 0.70 (2.397%)
Open: 29.50
High: 30.00
Low: 29.40
Prev. Close: 29.75
EKF Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Final Results

19 Apr 2006 07:00

Embargoed: 19th April 2006, 07:00hrs International Brand Licensing Plc ("IBL" or the "Company") Final Results to the year ended 31 December 2005 Chairman's StatementHighlights: * Turnover for the year ended 31 December 2005 increased by ‚£1,026,000 to ‚£ 3,261,000 (2004: ‚£2,235,000) * Profit on ordinary activities before tax improved by ‚£1,482,000 to a profit of ‚£977,000 (2004: loss of ‚£505,000) * A gain of ‚£475,000 was made on the sale of the Mountain Equipment trademarks * Record sales of England replica kit and substantial growth opportunities ahead For the year ended 31st December 2005 I am delighted to report a substantialturnaround in the Group's fortunes. 2005 was a year of consolidation, cuttingoverheads, improving gross margin, eliminating debt, and producing a full yearprofit for the first time in the Group's history.The 45% increase in turnover is attributable to the exceptional sales of theAdmiral England cricket replica kit that increased by 90% to a record level of‚£2,525,000 for the year. Boosted by England's tremendous Ashes win overAustralia, the Admiral brand enjoyed unprecedented visibility throughout theyear, and this continued unabated this winter, culminating in the marvellousthird Test victory over India in March 2006.With the return Ashes Series in Australia this winter, followed by the ICCCricket World Cup in the Caribbean and the India UK tour next summer, the levelof exposure that will continue to be generated for Admiral will further enhancethe profile and brand value for the future.Against a backdrop of difficult trading conditions in the UK retail sector thatfailed to recover through the year, Admiral sales at ASDA were some 15% down on2004. Certain product categories such as footwear and sports equipmentcontinued to perform well, but clothing suffered due to the heavy discountingthat plagued the UK market for much of the year. With the FIFA World Cup Finalsin Germany this summer we expect Admiral's first half clothing sales at ASDA toshow an overall improvement on 2005.In December the Company entered into a new strategic alliance with @miral BV,its licensee for Benelux, Germany, and Austria. As part of a new ten yearlicense agreement for this key central European territory, @miral will use itsextensive design, development, and marketing resources to develop seasonalprogrammes on an annual basis for IBL's network of international licensees.The Company continues to seek Admiral licensee partners in other majorinternational markets, particularly in several of the developing Asianeconomies where a significant amount of work has been undertaken. Negotiationsin certain markets are progressing well, and focus will continue to be appliedon untapped potential for the Admiral brand where opportunities for futuregrowth are substantial.IBL is now in a strong position to further enhance shareholder value. TheAdmiral brand continues to grow around the world, and as kit sponsors to theEngland and West Indies cricket teams we believe we have substantialopportunities in the years ahead. Your Board looks forward to the future withgreat confidence.ADAM REYNOLDSChairman19th April 2006For further information please contact:Adam ReynoldsPaul FoulgerInternational Brand Licensing plcTel: 020 7823 1733Katie Ratner/John PriorCorporate SynergyTel: 020 7448 4400Group Profit and Loss AccountFor the year ended 31 December 2005 2005 2004 ‚£000 ‚£000 Turnover 3,261 2,235 Cost of sales (1,286) (561) Gross Profit 1,975 1,674 Administrative expenses (1,402) (1,963) Operating Profit/(Loss) 573 (289) Exceptional profit on sale of intangible 475 -asset Interest receivable 6 - Interest payable (77) (216) Profit/(Loss) on ordinary activities before 977 (505)tax Tax on profit on ordinary activities (142) (84) Retained Profit/(Loss) for the year 835 (589) Earnings/(Loss) per ordinary share Before exceptional items - Basic 1.1p (1.9p) - Diluted 1.1p (1.9p) After exceptional items - Basic 2.5p (1.9p) - Diluted 2.5p (1.9p)Group statement of total recognised gains and lossesFor the year ended 31 December 2005 2005 2004 ‚£000 ‚£000 Profit/(Loss) for the year 835 (589) Exchange differences (236) 28 Total recognised gains and losses relating to the 599 (561)year Group balance sheetat 31 December 2005 2005 2004 ‚£000 ‚£000 Fixed assets Intangible assets 3,471 5,952 Tangible assets 9 15 3,480 5,967 Current assets Stock 252 217 Debtors 828 364 Cash at bank and in hand 283 109 1,363 690 Creditors: amounts falling due within one year (1,129) (3,542) Net current assets/(liabilities ) 234 (2,852) Total assets less current liabilities 3,714 3,115 Capital and reserves Share capital 333 333 Share premium 3,048 3,048 Merger reserve 244 244 Profit and loss account 89 (510) Shareholders' funds 3,714 3,115Group statement of cash flowsAt 31 December 2005 2005 2004 ‚£000 ‚£000 Net cash inflow/(outflow) from operating activities 111 (430) Returns on investments and servicing of finance Interest paid (80) (224) Interest received 6 - Taxation UK Tax paid (59) (198) Foreign taxes received 48 - Capital expenditure and financial investment Purchase of intangible fixed assets (37) (82) Capital Income Sale of intangible fixed assets 2,772 - Net cash inflow/(outflow) from capital expenditure 2,735 (82) and financial investment Net cash inflow/(outflow) before financing 2,761 (934) Financing Repayment of bank borrowing (2,563) (250) Issue of ordinary shares - 1,329 Less expenses of issue - (111) Net cash (outflow)/inflow from financing (2,563) 968 Increase in cash in the year 198 34The financial information set out in this announcement does not constitutestatutory accounts within the meaning of Section 240 of the Companies Act 1985.Statutory accounts for the period ended 31 December 2005, containing anunqualified auditors' report will be filed with the Registrar of Companies.The Directors do not propose a payment of a dividend.This preliminary statement was approved by the Board on 19 April 2006ENDINTERNATIONAL BRAND LICENSING PLC
Date   Source Headline
30th Apr 20213:52 pmRNSDirector/PDMR Shareholding
23rd Apr 20217:00 amRNSPosting of Annual Report &Accounts & Notice of AGM
22nd Apr 20217:00 amRNSDirector/PDMR Shareholding
30th Mar 20217:01 amRNSFinal Results
30th Mar 20217:00 amRNSTrading update & Expansion of supply agreement
10th Mar 202111:45 amRNSExecutive Performance Bonus
3rd Mar 20217:00 amRNSNotice of Results
19th Feb 20214:36 pmRNSPrice Monitoring Extension
22nd Jan 20214:41 pmRNSSecond Price Monitoring Extn
22nd Jan 20214:36 pmRNSPrice Monitoring Extension
12th Jan 20217:00 amRNSTrading Update
5th Jan 20213:37 pmRNSHolding(s) in Company
30th Dec 20205:56 pmRNSHolding(s) in Company
14th Dec 20207:00 amRNSApproval of dividend in specie
10th Dec 20201:09 pmRNSResult of General Meeting
2nd Dec 20207:00 amRNSGenomic testing service launch and Change of name
26th Nov 20207:01 amRNSHolding(s) in Company
26th Nov 20207:00 amRNSCOVID-SeroKlir - FDA Emergency Use Authorisation
26th Nov 20207:00 amRNSSale of shares in Renalytix AI plc
24th Nov 20207:00 amRNSUpdate on strategic investment in Trellus Health
9th Nov 20207:00 amRNSTrading update
28th Oct 20202:15 pmRNSRe-issued: EKF marketing & distribution agreement
28th Oct 20207:00 amRNSEKF & Kantaro partner to market antibody testing
26th Oct 20207:00 amRNSDividend confirmation
22nd Oct 20207:00 amRNSNew orders for COVID-19 sample collection kits
2nd Oct 20207:00 amRNSTrading update
1st Oct 20207:00 amRNSExercise of Options and Total Voting Rights
14th Sep 20206:14 pmRNSDividend Timetable Amendment
14th Sep 20207:00 amRNSHalf-year Report
10th Sep 202012:00 pmRNSNotice of Results
20th Aug 20207:00 amRNSStrategic investment
5th Aug 20207:01 amRNSExecutive Performance Bonus
5th Aug 20207:00 amRNSSupply contract for COVID19 sample collection kits
14th Jul 20207:00 amRNSUpdate on trading and COVID-19 related contract
24th Jun 20204:40 pmRNSSecond Price Monitoring Extn
24th Jun 20204:35 pmRNSPrice Monitoring Extension
12th Jun 20204:41 pmRNSSecond Price Monitoring Extn
12th Jun 20204:35 pmRNSPrice Monitoring Extension
10th Jun 20205:43 pmRNSResults of AGM
8th Jun 20204:41 pmRNSSecond Price Monitoring Extn
8th Jun 20204:36 pmRNSPrice Monitoring Extension
15th May 20207:00 amRNSUpdate on trading and COVID-19 related contract
7th May 20207:00 amRNSPosting of Annual Report & Accounts &Notice of AGM
6th May 202011:30 amRNSExercise of options and Total Voting Rights
5th May 20204:41 pmRNSSecond Price Monitoring Extn
5th May 20204:36 pmRNSPrice Monitoring Extension
5th May 20207:00 amRNSDistribution Agreement for Quo-Test HbA1c Analyzer
29th Apr 20207:00 amRNSUK contract for COVID-19 sample collection kits
28th Apr 20207:00 amRNSCOVID-19 related manufacturing capacity update
27th Apr 20207:00 amRNSUpdate on COVID-19 related manufacturing contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.